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The aim of this study was to determine the effect of prevention of the mother to child transmission (PMTCT) program 
in Benin City, Nigeria on the prevalence of postnatal infant HIV. Effects of the duration of PMTCT, place of birth and 
sex of the infants on the prevalence of postnatal HIV were also assessed. Dried blood spots were collected from 318 
infants (6−8 weeks old) born to HIV-positive mothers and were screened for the presence of HIV using a qualitative 
polymerase chain reaction method. A questionnaire was used to obtain information about the duration of highly 
active antiretroviral therapy (HAART) and place of delivery. Male infants had a significantly (p = 0.032) higher preva-
lence of postnatal HIV infection than females. Nonparticipation of mothers in the PMTCT program was a significant 
risk factor for acquiring postnatal HIV (odds ratio = 4.519; 95% confidence interval = 2.422, 8.429; p < 0.0001). The 
duration of HAART use significantly (p = 0.010) affected the prevalence of postnatal HIV with an inverse relationship. 
The place of delivery had no effect on the prevalence of postnatal HIV. An overall prevalence of 16.98% of postnatal 
HIV was observed in this study. Male sex and no participation in the PMTCT program were significant risk factors for 
acquiring postnatal HIV, while a lower prevalence of postnatal HIV infection was associated with longer use of HAART 
in the PMTCT program. We recommend an early diagnosis of maternal HIV status and commencement of HAART.
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Introduction
Mother to child transmission of HIV-1 is estimated 
to be the cause of at least 90% of pediatric HIV in-
fections, with more than 700,000 children newly 
infected in 2006 worldwide.1 An estimated 2.3 million 
children in sub-Saharan Africa are infected with 
HIV, most of whom acquire the virus around the time 
of birth.2 Prevention of mother to child transmission 
(PMTCT) is based on the use of highly active antiret-
roviral therapy (HAART) and elective caesarian de-
livery.3 Resource-rich countries are able to provide 
both, and HIV transmission from mother to child in 
this context is reported to be less than 20%.1 However, 
developing countries do not have access to these 
strategies.
Prevention of mother to child transmission in de-
veloping countries is mostly performed by the use 
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of antiretroviral therapy and the use of single dose 
nevirapine has been attempted in some African coun-
tries with 50% success.4,5 However, in Nigeria with 
the advent of the President’s Emergency Plan for AIDS 
Relief program, HAART is given freely to every HIV 
patient, thus making HAART available to every HIV-
positive pregnant woman.
The problem of stigmatization reduces the 
chances of early determination of the HIV status of 
pregnant women, which may increase the chances 
of mother to child transmission of the disease. In the 
African setting, pregnant women deliver at home or 
at various levels of health care with various degrees 
of awareness of the PMTCT program. This study 
determined the effect of PMTCT on the prevalence 
of HIV on infants as well as the effect of duration of 
PMTCT and place of birth on the prevalence of HIV 




This study was carried out in the University of 
Benin Teaching Hospital, Benin City, Nigeria. The 
hospital is a tertiary hospital with a referral status and 
is one of the sites for the Institute of Human Virology, 
Nigeria and the President’s Emergency Plan for 
AIDS Relief HIV/AIDS intervention program in the 
country. HIV testing, treatment and monitoring are 
rendered at no cost. The hospital also receives 
mothers with their newborn infants who may have 
delivered in locations outside the hospital.
Study population
The study population included infants (6−8 weeks 
old) born to HIV-positive mothers. The mothers com-
prised those who delivered in our hospital and par-
ticipated in the PMTCT program, as well as those 
who delivered outside the hospital. The latter group 
was screened for HIV using a previously described 
method.6 The infants of these women were used for 
this study. Verbal informed consent from each infant’s 
mother was obtained prior to sample collection. A 
questionnaire was used to collect information on the 
sex of infants, use of HAART for PMTCT by mothers 
of infants, duration of HAART use before delivery and 
place of delivery of infants. The PMTCT program 
entailed a combination of the use of HAART by moth-
ers and avoidance of breastfeeding infants. HAART 
agents used by the mothers included zidovudine, ne-
virapine and lamivudine. The dosage of HAART agents 
were as follows: 300 mg zidovudine, 200 mg nevirap-
ine and 150 mg lamivudine twice daily. The study 
protocol was approved by the Ethical Committee 
of the University of Benin Teaching Hospital.
Collection and processing of samples
Dried blood spots were collected from each infant 
and tested for HIV using a qualitative DNA polymer-
ase chain reaction (PCR) (AMPLICOR HIV-1 DNA test 
version 1.5; Roche, Basel, Switzerland).
Statistical analysis
Data were analyzed using the χ2 square test and 
odds ratio analysis was carried out using the sta-
tistical software INSTAT (GraphPad Software Inc., 
La Jolla, CA, USA).
Results
A total of 54 of the 318 infants (16.98%) were posi-
tive for HIV. The prevalence of HIV was signifi-
cantly higher in males (35/161, 27.72%) than that 
in females [19/157 (12.10%); p = 0.0324) and male 
sex was a risk factor for HIV infection [odds ratio 
(OR) = 2.018; 95% confidence interval (CI) = 1.098, 
3.708]. Use of antiretroviral therapy for PMTCT was 
not a risk factor for HIV acquisition among the in-
fants (OR = 0.221; 95% CI = 0.119, 0.413) as the prev-
alence of HIV was significantly (p < 0.0001) higher 
in those infants whose mothers did not use antiret-
rovirals than in those whose mothers did use 
antiretrovirals (Table 1).
Table 1 Effect of sex and PMTCT on the prevalence of HIV
Characteristics Tested n Positive for HIV n (%) OR 95% CI p 
Sex of offspring
 Male 161 35 (27.74) 2.018 1.098, 3.708  0.0324
 Female 157 19 (12.10) 0.496 0.270, 0.911 
PMTCT
 Yes 201 18 (8.96) 0.221 0.119, 0.413 < 0.0001
 No 117 36 (30.77) 4.519 2.422, 8.429
OR: odds ratio; CI: confidence interval; PMTCT: prevention of mother to child transmission.
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PMTCT program is a known method of preventing 
mother to child transmission of HIV infection.1,2
The duration of antiretroviral use before deliv-
ery significantly affected the prevalence of infant 
HIV infection. The longer the PMTCT use before 
delivery, the lower the prevalence. Therefore it is 
important to determine the HIV status of pregnant 
women to give HAART treatment to those who are 
HIV-positive, as this could be beneficial for reducing 
or totally eliminating mother to child transmission. 
However, further studies are needed to substantiate 
this reasoning.
More women who delivered in a tertiary hospital 
compared with those who delivered elsewhere 
were aware of the President’s Emergency Plan for 
AIDS Relief program including PMTCT (data not 
shown). All women who delivered at home and 
those who delivered in a primary health care centre, 
and a large proportion of women who delivered in 
a secondary health care centre had no information 
on PMTCT. However, because of the benefit of PMTCT 
and the duration of HAART, it is recommended that 
the PMTCT program be made available at all levels 
of the health system. It should be noted, however, 
that the place of delivery had no significant effect on 
the prevalence of HIV among the infants. This may 
be because of the presence of HIV and immune 
status of HIV-infected mothers as a low CD4 count 
is a risk factor for transmission of HIV infection 
in utero.9 The CD4 count of pregnant women was 
not assessed and all pregnant women used in this 
study had no signs or symptoms of opportunistic 
infection, which may indicate a high CD4 count.
This study revealed an overall infant HIV preva-
lence of 16.98%. Male sex and non-use of HAART 
for PMTCT were risk factors for acquiring HIV in-
fection for infants. The longer the use of HAART 
in HIV-positive mothers before delivery, the less 
likely it is they will give birth to an HIV-positive 
infant. Thus the use of antiretrovirals needs to be 
The predelivery duration of HAART use by moth-
ers significantly (p = 0.01) affected the prevalence 
of HIV infection among the infants with mothers 
who had used HAART 10−12 months before deliv-
ery had zero prevalence of HIV infection among 
their infants (Table 2). Although mothers who de-
livered in our tertiary institution and those who 
delivered at home had a lower prevalence of HIV 
infection in their infants compared with those who 
delivered in primary and secondary health institu-
tions, the difference was not statistically significant 
(Table 2).
Discussion
In developing countries such as Nigeria, people are 
often stigmatized because of HIV infection despite 
the availability of free services (testing and treat-
ment). In Nigeria, mothers also often give birth at 
home, either alone or assisted by traditional birth 
attendant. The majority of these mothers have 
varying levels of information on the country’s PMTCT 
program. The effect of these factors on the preva-
lence of infant HIV was investigated in this study.
We found that male infants have approximately 
a 1-fold to 4-fold increased risk of acquiring HIV 
infection compared with their female counter-
parts. This finding disagrees with earlier reports 
where no sex difference was observed.7,8 However, 
our results are consistent with the findings of an 
earlier study, where male sex was a risk factor for 
acquisition of late postnatal HIV infection.9 The 
reason for the high prevalence in male infants is 
unclear.
Mothers who took antiretrovirals before and 
during pregnancy (participated in the PMTCT pro-
gram) gave birth to infants with a lower prevalence 
of HIV compared with those who did not participate 
in the PMTCT program. Use of antiretrovirals in the 
Table 2  Effect of the duration of prevention of mother to child transmission and place of delivery on the prevalence 
of HIV
Characteristics Tested (n) HIV-positive n (%) p
Duration of HAART use before delivery (mo)   
 1−3 70 12 (17.14) 
 4−6 54 5 (9.26) 
 7−9 63 1 (1.59) 
 10−12 14 0 (0.00) 0.01
Place of delivery   
 Tertiary  185 8 (4.32) 
 Secondary 45 5 (11.11) 
 Primary 20 3 (15.00) 
 Home 68 2 (2.94) 0.0621
HAART: highly active antiretroviral therapy.
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expanded to all levels of health care responsible 
for antenatal services.
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